PUMA BIOTECHNOLOGY, INC. (PBYI) Operating cash flow 2016–2025
PUMA BIOTECHNOLOGY, INC. (PBYI) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
$41.8MFY2025 · since FY2016: -$141.7M → $41.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $41.8M | +7.4% |
| FY2024 | $38.9M | +44.1% |
| FY2023 | $27.0M | +270.7% |
| FY2022 | -$15.8M | -176.6% |
| FY2021 | $20.6M | +2571.4% |
| FY2020 | $773,000 | -96.5% |
| FY2019 | $22.4M | +192.8% |
| FY2018 | -$24.1M | +86.0% |
| FY2017 | -$172.5M | -21.7% |
| FY2016 | -$141.7M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More PBYI financial trends
PBYI RevenuePBYI Net incomePBYI Net marginPBYI Gross profitPBYI Gross marginPBYI Operating incomePBYI Operating marginPBYI Free cash flowPBYI Capital expendituresPBYI Return on equityPBYI Stock buybacksPBYI Dividends paidPBYI Total assetsPBYI Total liabilitiesPBYI Shareholders’ equityPBYI overview →